(Reuters) – GSK-owned Tesaro will pay rival AstraZeneca (AZN.L) royalties on sales of its ovarian cancer drug Zejra, a British court said on Wednesday. I ordered you.
Tesaro has filed a UK lawsuit against GSK in 2021 by AstraZeneca, seeking a greater percentage of its sales from Zejula, for sales for uses claimed or covered by licensed patents. claimed to be paid royalties only.
In October 2012, Tesaro entered into a licensing agreement with AstraZeneca, giving it exclusive rights to certain methods of treating Zejra patients that Tesaro developed with the help of technology licensed from AstraZeneca.
The High Court of Business and Property Courts of England and Wales said Wednesday that Tesaro will receive a royalties from AstraZeneca “for all net sales of Zejra in each country with a licensed patent from the first commercial sale in that country.” said it was obliged to pay the ti.with AstraZeneca.
“We are disappointed with today’s decision and are considering our next steps,” said a GSK spokesperson, but said AstraZeneca was happy with the decision.
The latest results from GSK, which acquired US-based oncology-focused company Tesaro for $5.1 billion in 2018, see Zejula’s sales of £463 million ($578.19 million) in 2022. ).
Zejula belongs to a family of drugs called PARP inhibitors, which includes Lynparza from AstraZeneca and Merck (MRK.N) and Lubraca from Clovis Oncology.
($1 = £0.8008)
Reported by Sinchita Mitra, Aby Koilparambil, and Yadarisa Shabong of Bangalore.Editing: Shinjini Ganguly
Our criteria: Thomson Reuters Trust Principles.
